Real world retrospective study of therapies in lung and thymic carcinoids - A study of the ENETS Lung Task Force

Level: Level 3

Launch date: 1. quarter of 2023

Principle investigators: Thomas WALTER & Anna KOUMARIANOU

Project description:

This study is organized by the ENETs Lung Task Force and aims to retrospectively collect real-world data on the clinical efficacy and the antineoplastic effect of SSA and PRRT in typical and atypical neuroendocrine NETs.

All data will be collected from ENETs multidisciplinary centers and centers specialized in the field, to guarantee quality data.

The primary endpoint of this study is to assess the PFS of patients with advanced lung and thymic carcinoids treated with SSA and PRRT.

The secondary objectives of this study are to assess the doses and duration of treatment, the clinical efficacy (symptomatic response), the toxicity of SSA and PRRT, DCR, PFS at 12 months and the OS.

Other treatment parameters will be analyzed such as presence of a functioning syndrome, sequence of treatments, effectiveness of rechallenge with the same treatment, occurrence and reasons of dose modifications. A cost-effectiveness analysis of these treatments will be included.

The dataset has also the function to record current clinical practices around collaborative ENETs groups, and to disseminate the results in the form of abstracts and publications.